Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Plus Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HOUSTON, JAN. 08, 2026 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC.(NASDAQ:PSTV) (PLUS OR THE COMPANY), A HEALTHCARE COMPANY DEVELOPING AND COMMERCIALIZING PRECISION DIAGNOSTICS AND RADIOPHARMACEUTICALS FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THE COMPLETION OF A TYPE B MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON NEXT STEPS ON REYOBIQ PIVOTAL TRIAL STRATEGY FOR LEPTOMENINGEAL METASTASES (LM). THE MEETING RESULTED IN CONSTRUCTIVE DISCUSSION WITH THE FDA REGARDING KEY ELEMENTS OF THE POTENTIAL PIVOTAL STUDY DESIGN FOR REYOBIQ IN LM.

PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ FOR LEPTOMENINGEAL METASTASES

CNSIDE DIAGNOSTICS NOW LICENSED IN 48 U.S. STATES COVERING OVER 90% OF THE U.S. POPULATION CNSIDE DIAGNOSTICS NOW LICENSED IN 48 U.S. STATES COVERING OVER 90% OF THE U.S. POPULATION

PLUS THERAPEUTICS EXPANDS CNSIDE ASSAY PLATFORM TO STATE OF CALIFORNIA

HOUSTON, DEC. 09, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC.(NASDAQ:PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCED TWO NEW HIRES TO ITS TEAM FOR CNSIDE DIAGNOSTICS, LLC, ITS WHOLLY-OWNED SUBSIDIARY.

PLUS THERAPEUTICS ANNOUNCES EXPANSION OF CNSIDE TEAM AND ISSUANCE OF INDUCEMENT GRANTS

COHORT 1 DATA FROM MULTIPLE DOSE RESPECT- LEPTOMENINGEAL METASTASES (LM) TRIAL SHOWED NO DOSAGE LIMITING TOXICITY

PLUS THERAPEUTICS HIGHLIGHTS THREE REYOBIQ CLINICAL DATA PRESENTATIONS AT 2025 WFNOS/SNO ANNUAL MEETING

HOUSTON, DEC. 01, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES THE ACCEPTANCE OF AN ABSTRACT FOR POSTER SPOTLIGHT (WITH ORAL) PRESENTATION AT THE UPCOMING SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS), BEING HELD ON DECEMBER 9-12, 2025, IN SAN ANTONIO, TX. POSTER SPOTLIGHT PRESENTATION: TITLE RHENIUM (186RE) OBISBEMEDA (RHENIUM NANOLIPOSOME, 186RNL) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM): PHASE 1 DOSE ESCALATION STUDY RESULTS  PRESENTER ANDREW BRENNER, M.D.

PLUS THERAPEUTICS TO PRESENT RESPECT PHASE 1 DOSE ESCALATION STUDY RESULTS FOR LEPTOMENINGEAL METASTASES AT THE 2025 SAN ANTONIO BREAST CANCER SYMPOSIUM

HOUSTON, NOV. 24, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A HEALTHCARE COMPANY DEVELOPING AND COMMERCIALIZING PRECISION DIAGNOSTICS AND RADIOPHARMACEUTICALS FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCED IT HAS COMPLETED A TYPE B MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON NOVEMBER 7TH TO DISCUSS ITS REYOBIQ CLINICAL DEVELOPMENT PLANS FOR LEPTOMENINGEAL METASTASES (LM) INCLUDING THE DESIGN OF A PLANNED PIVOTAL OR REGISTRATIONAL TRIAL.

PLUS THERAPEUTICS ANNOUNCES COMPLETION OF U.S. FDA MEETING ON FUTURE CLINICAL DEVELOPMENT PLANS FOR REYOBIQ IN LEPTOMENINGEAL METASTASES

HOUSTON, NOV. 20, 2025 (GLOBE NEWSWIRE) -- CNSIDE DIAGNOSTICS, LLC, A WHOLLY-OWNED SUBSIDIARY OFPLUS THERAPEUTICS, INC.(NASDAQ:PSTV) (PLUS OR THE COMPANY), ANNOUNCED TODAY THAT IT HAS SIGNED A NATIONAL AGREEMENT WITH HUMANA, INC. (NYSE: HUM), EFFECTIVEOCTOBER 29, 2025, COVERING APPROXIMATELY 16 MILLION PEOPLE THROUGHOUTTHE UNITED STATES, TO PROVIDE THE CNSIDE CEREBROSPINAL FLUID (CSF) TUMOR CELL ENUMERATION (TCE) LABORATORY DEVELOPED TEST (LDT). THIS BRINGS CNSIDE CSF TCE LDT TOTAL POLICY COVERAGE TO 67 MILLION PEOPLE.

PLUS THERAPEUTICS SECURES NATIONAL COVERAGE AGREEMENT WITH HUMANA FOR CNSIDE CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER

HOUSTON, NOV. 17, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ: PSTV) (PLUS OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, TODAY ANNOUNCES IT HAS RECEIVED AN ADDITIONAL 180-DAY EXTENSION PERIOD FROM THE NASDAQ LISTING QUALIFICATIONS DEPARTMENT (THE NASDAQ STAFF) TO REGAIN COMPLIANCE WITH THE $1.00 MINIMUM BID PRICE REQUIREMENT SET FORTH IN NASDAQ LISTING RULE 5550(A)(2) (THE MINIMUM BID PRICE REQUIREMENT). THE EXTENSION NOTICE HAS NO IMMEDIATE EFFECT ON THE CONTINUED LISTING STATUS OF THE COMPANY'S COMMON STOCK ON THE NASDAQ CAPITAL MARKET (NASDAQ) UNDER THE SYMBOL PSTV.

PLUS THERAPEUTICS GRANTED 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT

LEPTOMENINGEAL METASTASES DISEASE SESSION FEATURES NOVEL TREATMENTS IN THE HORIZON, REYOBIQ AND RESPECT-LM, AND FUTURE DIRECTIONS AND NEEDS LEPTOMENINGEAL METASTASES DISEASE SESSION FEATURES NOVEL TREATMENTS IN THE HORIZON, REYOBIQ AND RESPECT-LM, AND FUTURE DIRECTIONS AND NEEDS

PLUS THERAPEUTICS HIGHLIGHTS RESPECT-LM CLINICAL TRIAL RESULTS AT 40TH SITC ANNUAL MEETING, MELANOMA RESEARCH FOUNDATION BRAIN METASTASES SUMMIT 4.0

US MARKET INTRODUCTION OF THE CNSIDE CSF DIAGNOSTICS PLATFORM, WITH FIRST NATIONAL COVERAGE AGREEMENT WITH UNITEDHEALTHCARE

PLUS THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

EXPANDS COMMERCIAL READINESS AND DIAGNOSTIC, MANUFACTURING FOOTPRINT APPOINTS NEW LEADERSHIP IN COMMERCIAL STRATEGY AND TECHNICAL OPERATIONS HOUSTON, OCT. 21, 2025 (GLOBE NEWSWIRE) -- PLUS THERAPEUTICS, INC. (NASDAQ:PSTV) (THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING TARGETED RADIOTHERAPEUTICS WITH ADVANCED PLATFORM TECHNOLOGIES FOR CENTRAL NERVOUS SYSTEM (CNS) CANCERS, ANNOUNCES CONTINUED OPERATIONAL EXECUTION AND COMMERCIAL PROGRESS IN THE LAUNCH OF ITS WHOLLY OWNED SUBSIDIARY, CNSIDE DIAGNOSTIC LLC'S, CEREBROSPINAL FLUID (CSF) TUMOR CELL ENUMERATION LABORATORY DEVELOPED TEST (LDT). RECENT ACCOMPLISHMENTS INCLUDE EXPANSION OF THE CNSIDE MANUFACTURING FOOTPRINT, ADVANCEMENTS IN COMMERCIAL READINESS AND APPOINTMENTS IN KEY LEADERSHIP POSITIONS TO PROPEL THE CNSIDE DIAGNOSTIC BUSINESS FORWARD.

Plus Therapeutics, Inc.

PSTV

Price

Financial Reports

No items found.

Press Releases

Plus Therapeutics, Inc.

PSTV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PSTV